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Background: Ectopic hepatic lipid accumulation is closely related to the development of insulin resistance, which is
regarded as one of the most significant risk factors of non-alcoholic fatty liver disease (NAFLD). The current study
has shown that fat tissue constitutes an important endocrine organ with its own production and metabolism of
many biologically active substances, among which adipokines play an important role. Classic adipokines (e.g. leptin,
adiponectin, resistin) are fat-derived hormones which serum level is altered in patients with NAFLD. The role of
novel adipokines in the pathomechanism of this disease is not clear. Therefore, the aim of our study was to evaluate
the serum concentrations of chemerin, omentin and vaspin in obese children with NAFLD.
Methods: Forty-five obese children, aged 7–17 years old, were admitted to our Department with suspected liver
disease (hepatomegaly, and/or ultrasonographic liver brightness, and/or increased ALT activity). Viral hepatitides, as
well as autoimmune and metabolic liver diseases were excluded. Fasting serum levels of chemerin, omentin and
vaspin were determined. The grade of liver steatosis in ultrasound was graded according to Saverymuttu. 1HMR
spectroscopy was performed with a 1.5 T scanner and with PRESS sequencing.
Results: Fatty liver was confirmed in 39 children by ultrasound and in 33 patients by 1HMRS (19 of them also had
increased ALT activity /NAFLD/). Chemerin and vaspin levels were significantly higher in children with NAFLD
compared to the control group (n = 30). The concentration of chemerin was significantly higher in children with
advanced liver steatosis compared to non-hepatopathic patients (p = 0,02). Significant positive correlations were
found between the total liver lipids in 1HMRS and chemerin (r = 0,33; p = 0,02) and vaspin (r = 0,4; p = 0,006). The
ability of serum chemerin (cut-off = 190 ng/ml, Se = 75%, Sp = 58%) to differentiate children with fatty liver in 1HMRS
from those without steatosis was significant (AUC = 0,7, p = 0,04). Omentin and vaspin did not allow a useful
prediction to be made.
Conclusion: Chemerin seems to be the most suitable non-invasive biomarker in predicting both intrahepatic
lipid content in obese children and advanced liver steatosis in children with NAFLD.
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Due to the increase in obesity prevalence observed through-
out the world during the last few decades, nonalcoholic
fatty liver disease (NAFLD) has become the most com-
mon cause of chronic liver disease, both in adults and
children [1]. NAFLD is commonly associated with vis-
ceral obesity, dyslipidemia and insulin resistance, which* Correspondence: lebensztejn@hoga.pl
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article, unless otherwise stated.constitutes the specific manifestation of metabolic syn-
drome [2]. Results from many studies have confirmed that
both metabolic syndrome and NAFLD contribute to an
acceleration of atherosclerosis development. Moreover, in-
dividuals with NAFLD are at much higher risk of develop-
ing cardiovascular disease (CVD) compared to individuals
in the general population [3,4]. Additionally, fat distri-
bution seems to be a better predictor of (CVD) compared
to obesity alone [5]. It has been proven that not only
visceral obesity, but also ectopic fat accumulation in the
liver is strictly associated with the development of insulinCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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current study has shown that fat tissue constitutes an im-
portant endocrine organ with its own production and me-
tabolism of many biologically active substances, among
which adipokines play an important role [8]. These pro-
teins, produced and secreted by fat tissue, take part in
many physiological processes and are responsible for such
pathological changes associated with obesity as insulin re-
sistance, atherosclerosis, hypertension and NAFLD. Lately,
it has been suggested that so called “novel” adipokines
(chemerin, omentin, vaspin) might have a strong relation-
ship with obesity, insulin resistance, atherosclerosis, meta-
bolic syndrome and fatty liver. It has been shown in a few
studies, comprised of adult populations, that some of
these adipokines are displayed in higher concentrations in
NAFLD patients compared to the control. They may have
an important role in progression from simple steatosis to
inflammation and fibrosis. Moreover, a correlation was
found between their serum concentrations and the mor-
phological features of NAFLD (hepatocytes ballooning,
NAS index, fibrosis) [9-12]. However, an accurate assess-
ment of the role of the above mentioned adipokines is still
lacking in the pediatric population. It should be empha-
sized that the studies performed in children may be more
convincing compared to those in adults, due to the exist-
ence of far fewer confounding factors in such a population
and the fact that disease is usually less advanced. There-
fore, the objective of this study was to evaluate serum che-
merin, omentin and vaspin concentrations in children
with NAFLD as potential markers of ectopic lipid accu-
mulation in the liver.
Methods
This prospective study included a group of 45 consecutive
obese children (35 boys and 10 girls) aged 7–17 years
old (mean 13 years old) admitted to our Department in
2011–2012 due to suspected liver pathology (hepatomegaly
and/or elevated alanine aminotransferase/ALT/ and/or
fatty liver features in ultrasound/US/examination), as pre-
viously described [13]. Informed consent was obtained
from all patients’ parents. The protocol was approved by
the bioethics committee of the Medical University of
Bialystok.
Viral infection due to hepatitis C virus (HCV) and due to
hepatitis B virus (HBV), autoimmune hepatitis, chosen
metabolic liver diseases (Wilson disease, alpha-1-antitrypsin
deficiency, cystic fibrosis) and drug-induced liver injury
(DILI) were excluded in all children. Moreover, children
with diabetes and those receiving drugs that could affect
lipid or carbohydrate metabolism were excluded from
this study.
All subjects underwent physical examination with an-
thropometric measurements (body mass index/BMI/, which
was calculated from measurements of height and weight,and waist circumference). Routine blood chemistry analyses
(ALT, gamma glutamyltransferase/GGT/, total choles-
terol, high-density lipoprotein/HDL/ and low-density
lipoprotein/LDL/cholesterol, triglycerides/TG/, glucose
and insulin) were performed using standard methods.
Homeostatic model assessment –insulin resistance/
HOMA-IR/ was calculated according to the formula
described by Matthews et al. [14].
Fasting serum adipokine concentration (chemerin, omen-
tin, vaspin) was assessed using the commercial ELISA kits
(BioVender, Brno, Czech Republic). The control group was
comprised of 30 non-obese children without any somatic
organ pathology. Blood samples were immediately centri-
fuged and stored in −80°C until further processing. The
intra- and inter-assay CVs of chemerin ranged from 5.1 to
7.0% and 6.9 to 8.3% respectively. The intra- and inter-
assay CVs of vaspin ranged from 6.5 to 8.7% and 5.8 to
9.5% respectively. The intra- and inter-assay CVs of omen-
tin α ranged from 3.2 to 4.1% and 4.4 to 4.8% respectively.
All assays were conducted according to the manufacturer’s
instructions.
Liver ultrasound examination was performed with General
Electric Voluson E8, convex sonde 3–5 MHz; the intensity
of steatosis was assessed using a four-grade scale (0–3) as
outlined by Saverymuttu et al. [15]. Advanced liver steato-
sis was defined as a score >1. Steatosis grade was assessed
in a blinded fashion by the same radiologist without
knowledge of the patients’ laboratory or clinical data.
1HMR spectroscopy was performed with a 1.5 T scanner
(Picker Eclipse) and with PRESS sequencing. Total intra-
hepatic lipid content was assessed in relative units (r.u.) in
comparison to unsuppressed water signal. Voxele’s size
3×3×3 cm (27 cm3) was localized in the right liver lobe in
the manner that it would not comprise the vessels and bile
ducts [16].
Thirty nine children (87%) had liver steatosis in ultra-
sound examination (group I); 19 of them also had an in-
creased serum ALT activity (group Ia – NAFLD). Six
children (13%) had neither liver brightness in ultrasound
nor increased ALT activity (group II – non-hepatopathic
obese children) (Table 1).
Statistical analysis
The serum concentrations of adipokines, other biochem-
ical tests and anthropometric parameters were expressed
as median; 25–75 quartile. The statistical analysis was
performed with the Mann–Whitney two-sample test for
nonparametric data. The relationship between biochem-
ical tests was analyzed by the Spearman rank-correlation
test for non-parametric data. The tests were considered
statistically significant at p < 0.05. Logistic regression ana-
lysis was performed using IBM SPSS Statistics 20.0.
The receiver operating characteristics (ROC) analysis
was used to calculate the power of the assays to detect














Chemerin (ng/ml) 228.5; 178.4-251 229.4; 192.3-251.0 186; 159.5-201.8 0.06 (NS) 0.028
Vaspin (ng/ml) 0.09; 0.03-0,21 0.11; 0.036-0.42 0.07; 0.02-0.16 NS NS
Omentin (ng/ml) 194.5; 156.4-300.8 233.6; 163.0-335.1 201.5; 189.6-229.3 NS NS
Age (years) 14; 12-16 14; 13-16 11; 10-14 NS NS
BMI (kg/m2) 27.4; 26.0-32.2 28.8; 26.8-32.5 25.4; 25.4-28.2 NS 0,02
Waist (cm) 97.5; 92-105 101; 96-107 85.5; 81-98 0.05 0.01
ALT (IU/l) 37; 27-57 57; 50-84 17.5; 15-28 0.008 0.0002
GGT (IU/l) 24; 18-31 30; 23-45 13.5; 10-18 0.006 0.001
Cholesterol (mg/dl) 178; 143-210 180; 139-220 141.5; 130-182 NS NS
HDL-cholesterol (mg/dl) 44; 39-54 42; 39-51 43; 40-50 NS NS
LDL-cholesterol (mg/dl) 110; 82-130 108; 81-143 77; 73-105 NS NS
TG (mg/dl) 111; 68-152 140; 64-182 87.5; 75-126 NS NS
Glucose (mg/dl) 92; 89-97 94; 85-101 93; 89-96 NS NS
Insulin (μIU/ml) 13.3; 10.3-17.4 15.5; 10.3-21.0 14; 9.6-18.4 NS NS
HOMA-IR 3.08; 2.39-3.88 3.67; 2.42-4.49 3.4; 2.1-4.0 NS NS
Lipids 1HMRS (r.u.) 107; 79-163 139; 102-179 19.5; 14-38 0.006 0.004
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(AUC) was performed using a two-tailed p-test, which
compares the AUC to the diagonal line of no informa-
tion (AUC 0.5) [17].
Results
There were significantly higher BMI and waist circum-
ferences, activity of ALT and GGT and intrahepatic lipid
content in 1HMRS in children with NAFLD compared
to non-hepatopathic patients (Table 1).
Serum concentration of chemerin, vaspin and omentin
The serum levels of chemerin (229.4; 192.3-251.0 ng/ml)
and vaspin (0.11; 0.036-0.42 ng/ml) in NAFLD chil-
dren were significantly higher than in lean controls (113.5;
98.2-130.5, 0.04; 0.02-0.11 ng/ml respectively) (p < 0.0001;
p = 0.019 respectively). There were no significant differ-
ences in omentin in both groups; however, a lower value
of omentin was found in NAFLD patients (233.6; 163.0-
395.1 vs 311.9; 583.3-738.6 ng/ml). There was a sig-
nificant positive correlation of chemerin with: GGT
(r = 0.3; p = 0.03), an intensity of the hepatic steatosis in
US (r = 0,3; p = 0,04) and intrahepatic lipid content in
HMRS (r = 0.33; p = 0.02). Vaspin correlated with ALT and
GGT (r = 0.33; p = 0.02, r = 0.34; p = 0.02, respectively), in-
tensity of the hepatic steatosis in US (r = 0.3; p = 0.04) and
intrahepatic lipid content in 1HMRS (r = 0.4; p = 0.0006).
Omentin correlated only with total cholesterol (r = 0.3;
p = 0.04) and LDL-cholesterol (r = 0.3; p = 0.05).Nineteen children had advanced liver steatosis (grade 2
or 3) and 6 had no steatosis according to the Saverymuttu
scale [15]. The concentration of chemerin was signifi-
cantly higher in children with advanced liver steatosis
compared to non-hepatopathic patients (p = 0.02) (Table 2).
Diagnostic value of novel adipokines for identification of
patients with liver steatosis confirmed in 1HMRS
We confirmed liver steatosis in 33 children in 1HMRS.
Children with diagnosed liver steatosis in 1HMRS had
higher levels of chemerin, ALT, triglycerides and an
intensity of the hepatic steatosis in ultrasound examin-
ation (Table 3).
In the logistic regression analysis it was demonstrated
that only chemerin, one out of three tested adipokines,
may be useful in the differentiation of obese patients
with confirmed hepatic steatosis in 1HMRS from pa-
tients without steatosis (OR-1.018, 95% CI 1.001-1.035,
p = 0.044). Among other anthropometric and biochem-
ical parameters evaluated in our study, only trigli-
cerdes (OR-1.019, 95% CI 1.004-1.034, p = 0.012)
presented the differentiation capacity for both condi-
tions (Table 4).
This finding was confirmed in ROC analysis. The ability
of chemerin (cut-off = 190 ng/ml, Se = 75%, Sp = 58%) to
differentiate the children with liver steatosis in 1HMRS
from those without steatosis was significant (AUC = 0.7,
p = 0.04). Omentin and vaspin did not allow a useful pre-
diction to be made (Figure 1).
Table 2 The characteristics of subgroups of children with
advanced liver steatosis in US (n = 19) and without liver
steatosis in US (n = 6)
Parameter USG - 0
(n = 6)
median; Q1- Q3




Chemerin (ng/ml) 186; 159.5-201.8 229.4; 196.6-254.6 0.02
Vaspin (ng/ml) 0.07; 0.02-0.16 0.18; 0.04-0.4 NS
Omentin (ng/ml) 201.5; 189.6-229.3 193.9; 166-279 NS
Age (years) 11; 10-14 14; 12-16 NS
BMI (kg/m2) 25.4; 25.4-28.2 27.9; 27–32.5 0.04
Waist (cm) 85.5; 81-98 102; 94-107 0.01
ALT (IU/l) 17.5; 15-28 46; 33-72 0.003
GGT (IU/l) 13.5; 10-18 27; 22-31 0.002
Cholesterol (mg/dl) 141.5; 130-182 177; 140-192 NS
HDL-cholesterol (mg/dl) 43; 40-50 40; 37-50 NS
LDL-cholesterol (mg/dl) 77; 73-105 95; 79-121 NS
TG (mg/dl) 87.5; 75-126 123; 82-182 NS
Glucose (mg/dl) 93; 89-96 95; 89-101 NS
Insulin (μIU/ml) 14; 9.6-18.4 13.1; 12.1-17.5 NS
HOMA-IR 3.4; 2.1-4.0 3.3; 2.7-4.1 NS
Lipids 1HMRS (r.u.) 19.5; 14-38 154; 102-181 0.001
Table 3 The comparative characteristics of obese children wit
liver steatosis in 1HMRS (n = 12)
Parameter Lack of liver steatosis in 1HM
(n = 12)
median; Q1 -Q3
Chemerin (ng/ml) 186; 159.8-227.8
Vaspin (ng/ml) 0.09; 0.02-0.19
Omentin (ng/ml) 176.3; 136.9-239.1
Age (years) 14; 11–15.5
BMI (kg/m2) 28.1; 25.7-30.9
Waist (cm) 95.0; 89–103.5
ALT (IU/l) 36; 15–42.5
GGT (IU/l) 19.5; 11.5-23.5
Cholesterol (mg/dl) 177; 137-198
HDL – cholesterol (mg/dl) 48.5; 43–51.5
LDL – cholesterol (mg/dl) 108; 74-136
TG (mg/dl) 84.5; 61–111.5
Glucose (mg/dl) 92.5; 88.5-96.5
Insulin (μIU/ml) 13.5; 9.5-17.3
HOMA-IR 3; 2.03-3.96
Steatosis grade in US 1.0; 0.0-1.0
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In our study, significantly higher serum chemerin and
vaspin concentrations were found in obese children with
NAFLD compared to the control. However, no signifi-
cant differences in omentin serum concentration were
observed in either group. This type of study is currently
lacking in the pediatric population. Partially consistent
results have been achieved in a few studies in adults with
morphologically confirmed NAFLD, although the three
novel adipokines (simultaneously examined in this study)
were not assessed at the same time in any of them. Kukla
et al. [9] and Sell et al. [18] have demonstrated higher
serum chemerin concentration and Yilmaz et al. [19] have
also found higher chemerin and omentin concentrations
in patients with NAFLD compared to the control group.
Genc et al. [20] have confirmed higher serum concen-
tration of vaspin in patients with NASH compared to
the control. No differences in chemerin concentration
in patients with NAFLD and controls were found by
Ye et Al. [21]; however, it should be noted that NAFLD
was diagnosed on the basis of incomplete criteria, namely
by stating the characteristics of the fatty liver in US exam-
ination. The different concentrations of evaluated adipo-
kines in children with NAFLD compared to the healthy
population reflect their implication in the pathogenesis of
this disease.
However, the main objective of this study was to deter-
mine whether the examined novel adipokines can be con-
sidered as non-invasive biomarkers of ectopic, intrahepatich diagnosed liver steatosis in 1HMRS(n = 33) and without




















Table 4 Logistic regression analysis to differentiate of
obese patients with confirmed hepatic steatosis in
1HMRS from patients without steatosis
Parameter B OR 95% CI p
Chemerin 0.02 1.018 1.001-1.035 0.044
Vaspin 0.80 2.223 0.158-31.229 0.554
Omentin 0.00 1.004 0.994-1.015 0.404
ALT 0.01 1.014 0.973-1.056 0.514
GGT 0.02 1.020 0.960-1.083 0.522
Cholesterol 0.00 1.002 0.986-1.019 0.789
HDL-cholesterol −0.02 0.976 0.920-1.035 0.417
LDL-cholesterol 0.00 0.998 0.979-1.018 0.863
TG 0.02 1.019 1.004-1.034 0.012
Glucose 0.02 1.019 0.935-1.112 0.664
Insulin 0.02 1.022 0.912-1.145 0.709
HOMA-IR 0.09 1.097 0.686-1.752 0.699
BMI −0.04 0.965 0.814-1.143 0.680
Waist 0.01 1.012 0.958-1.068 0.676
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shown a positive correlation between chemerin and vaspin
concentration and the severity of steatosis and lipid con-
tent in the liver in imaging studies; however omentin did
not correlate with the above parameters.
In a study with adults, only Chen et al. [22] confirmed
the correlation between chemerin concentration and the
severity of steatosis assessed by magnetic resonance, but
those studies were performed on hemodialysis patients,
not patients with NAFLD.
Genc et al. [20] showed no vaspin correlation with stea-
tosis confirmed in a morphological study of the liver inFigure 1 ROC curve of ability of chemerin to detect children
with liver steatosis in 1HMRS.patients with NAFLD. However, chemerin was not evalu-
ated in this group. In our study, ectopic fat accumulation
in the liver was assessed by using proton magnetic reson-
ance spectroscopy (1HMRS), which is considered to be a
reliable, non-invasive diagnostic method [23,24]. A liver
biopsy, which is considered the “gold standard”, was not
performed in our study. This procedure is invasive, may
be associated with risk of complications, and the obtained
morphological results would not change or influence the
therapeutic procedure [25]. Therefore, the currently ac-
cepted criteria for liver biopsy in children, established by
Roberts [26], indicate that a liver biopsy in children with
suspected NAFLD should be performed only in very spe-
cific cases (suspected advanced disease process, the exclu-
sion of co-existing diseases, in patients up to 10 years of
age and with high serum ALTactivity, and before initiating
pharmacological intervention). The examined children in
our study did not meet the criteria necessary to perform a
liver biopsy.
To date, there is no data stating the predictive value of
examined adipokines for the diagnosis of fatty liver in
obese children. In the above analysis, we observed higher
concentrations of chemerin in children with hepatic
steatosis confirmed in 1HMRS compared to the group of
obese children without liver pathology. This observa-
tion was confirmed in the ROC analysis: the ability of
serum chemerin to differentiate children with fatty liver
in 1HMRS from those without steatosis was significant.
Omentin and vaspin did not allow a useful prediction
to be made.
Furthermore, in our study we have shown that among
the analyzed adipokines only chemerin differentiated
children with advanced hepatic steatosis from the non-
hepatopathic obese. Therefore, it seems that chemerin
can be considered a suitable biomarker of intrahepatic
lipid content in obese children.
Although the study performed using animal models to
assess chemerin expression in hepatic tissue is not con-
clusive [27], a recent study in humans has confirmed a
high expression of chemerin mRNA in hepatocytes [28].
Moreover, a correlation between necroinflammatory ac-
tivity and chemerin concentration in the serum of adults
with NAFLD has been shown [29]. Studies conducted in
pediatric populations confirmed that chemerin may be
regarded as a marker of systemic and vascular inflamma-
tion [30,31]. The above analysis has confirmed the cor-
relation between chemerin and ALT activity, which may
be regarded as an indicator of inflammatory processes in
the liver. Thus, it seems that children with NAFLD who
demonstrate high chemerin serum concentrations may
not only present simple fatty liver, but also its progres-
sion to NASH.
Our work has several potential limitations. Besides the
lack of morphological examination in the studied group,
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as discussed above, a selection bias should be mentioned,
since examined patients were recruited from a tertiary
center, which focuses on pediatric hepatology. As a result
of this, children with previously suspected pathology of
the liver were referred to the center and included to the
study group later. The relatively small sample size limits
the generalizability of our findings.
However in conclusion, the obtained data allow us to
suggest that chemerin plays a role in the pathogenesis of
NAFLD in children. Chemerin seems to be the most
suitable non-invasive biomarker in predicting both intra-
hepatic lipid content in obese children and advanced
liver steatosis in children with NAFLD.
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